Insights

What do brokers think of the ResMed (ASX:RMD) share price dip?

The ResMed Inc (ASX: RMD) share price took a dive last Friday on disappointing quarterly results. Could this be a buy the dip moment?
The post What do brokers think of the ResMed (ASX:RMD) share price dip? appeared first on The Motley Fool Australia. –

falling asx share price represented by girl falling asleep at her computer

The ResMed Inc (ASX: RMD) share price continues to take a beating on Monday after releasing its third-quarter results last week. Its shares have lost almost 9% in the last two trading sessions. 

At the time of writing, the ResMed share price is down 5.24%, trading at $24.80.

Why is the ResMed share price under pressure?

The narrative for the ResMed share price is similar to that of Kogan.com Ltd (ASX: KGN)Redbubble Ltd (ASX: RBL) and Temple & Webster Group Ltd (ASX: TPW).

COVID-19 supercharged the demand for ResMed products such as ventilators, masks and circuits. As the global pandemic unwinds, companies are finding it challenging to surpass elevated earnings experienced in FY20. 

Brokers weigh in on the dip 

Citi: Undervalued but cautious 

ResMed continues to perform well operationally under a difficult environment, according to Citi. The broker believes that are many upsides for the business in a post-COVID world, including higher market growth with the return of its previous sleep apnea patients, market share gains with its new Airsense 11 device and increased penetration in the chronic obstructive pulmonary disease (COPD) market. 

Citi believes the RedMed share price is about 10% undervalued but cautiously downgraded its rating from buy to neutral. Its target priced also retreated from $29.00 to $28.50. 

Credit Suisse: Tough comparables but industry upside in FY22 

Credit Suisse describes the March quarter result as a disappointment at the revenue level, although the company is cycling a period of tough comparables. 

Looking ahead, the broker eyes ResMed’s new CPAP device, AirSense 11, which is expected to be widely launched in the US by the end of 2021. The broker believes the industry will enter a resupply cycle in FY22 for devices, forecasting approximately 11% device growth in the US. 

Credit Suisse retained an outperform rating and slightly lowered its share price target from $29.50 to $29.00. 

Macquarie: Medium-term forecasts are unchanged 

The March quarter results were below Macquarie’s expectations, but gradual recovery in new patient growth is anticipated across 2021-22. 

The broker remains positive in the medium-term, leaving forecasts unchanged. A neutral rating was retained, and the target price reduced from $28.00 to $27.50. 

Morgans: Current headwinds are more cyclical than structural 

Morgans described the current headwinds for the business as cyclical rather than structural. It believes an upgrade cycle is imminent, with its next-generation sleep apnea platform due for commercialisation by the end of the year. 

Looking at the third-quarter result, the broker felt the performance was mixed as underlying revenue growth was flat, gross margins were contracting on higher costs and an unfavourable product mix. However, profit was slightly ahead of expectations on lower opex,  improving patient flows and ongoing mask resupply. 

Morgans rated the ResMed share price as an add but lowered its target price from $30.09 to $29.14.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Kogan.com ltd and Temple & Webster Group Ltd. The Motley Fool Australia has recommended Kogan.com ltd, ResMed Inc., and Temple & Webster Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post What do brokers think of the ResMed (ASX:RMD) share price dip? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!